These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 12806636)

  • 1. How safe are the safest IBD drugs?
    Lewis JD
    Gastroenterology; 2003 Jun; 124(7):1986-7; discussion 1987-8. PubMed ID: 12806636
    [No Abstract]   [Full Text] [Related]  

  • 2. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines.
    Ransford RA; Langman MJ
    Gut; 2002 Oct; 51(4):536-9. PubMed ID: 12235076
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mesalazine is safe for the treatment of IBD.
    D'Haens G; van Bodegraven AA
    Gut; 2004 Jan; 53(1):155. PubMed ID: 14684596
    [No Abstract]   [Full Text] [Related]  

  • 4. Comparative tolerability of treatments for inflammatory bowel disease.
    Stein RB; Hanauer SB
    Drug Saf; 2000 Nov; 23(5):429-48. PubMed ID: 11085348
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 5-Aminosalicylic acid (5-ASA) and chronic tubulointerstitial nephritis in patients with chronic inflammatory bowel disease: is there a link?
    De Broe ME; Stolear JC; Nouwen EJ; Elseviers MM
    Nephrol Dial Transplant; 1997 Sep; 12(9):1839-41. PubMed ID: 9306332
    [No Abstract]   [Full Text] [Related]  

  • 6. Mesalamine intolerance mimics symptoms of active inflammatory bowel disease.
    Iofel E; Chawla A; Daum F; Markowitz J
    J Pediatr Gastroenterol Nutr; 2002 Jan; 34(1):73-6. PubMed ID: 11753169
    [No Abstract]   [Full Text] [Related]  

  • 7. Mesalazine-associated acute tubulointerstitial nephritis in a patient with spondylarthropathy.
    Sari I; Birlik M; Cavdar C; Sarioglu S; Akpinar H; Onen F; Akkoc N
    N Z Med J; 2005 Sep; 118(1222):U1662. PubMed ID: 16222356
    [No Abstract]   [Full Text] [Related]  

  • 8. [Adverse effects of sulfasalazine: discussion of mechanism and role of sulfonamide structure].
    Atheymen R; Affes H; Ksouda K; Mnif L; Sahnoun Z; Tahri N; Zeghal KM; Hammami S
    Therapie; 2013; 68(6):369-73. PubMed ID: 24356188
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of tumor necrosis factor-α inhibitors on drug-induced pancreatitis in inflammatory bowel disease.
    Stobaugh DJ; Deepak P
    Ann Pharmacother; 2014 Oct; 48(10):1282-7. PubMed ID: 24982311
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mesalazine-induced interstitial nephritis.
    Skalova S; Dedek P; Pozler O; Podhola M
    Ren Fail; 2009; 31(2):159-61. PubMed ID: 19212915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Review article: interstitial nephritis associated with the use of mesalazine in inflammatory bowel disease.
    Corrigan G; Stevens PE
    Aliment Pharmacol Ther; 2000 Jan; 14(1):1-6. PubMed ID: 10632639
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sulphasalazine and mesalazine: serious adverse reactions re-evaluated on the basis of suspected adverse reaction reports to the Committee on Safety of Medicines.
    Logan RF; van Staa TP
    Gut; 2003 Oct; 52(10):1530; author reply 1530-1. PubMed ID: 12970150
    [No Abstract]   [Full Text] [Related]  

  • 13. The Association of Mesalamine With Kidney Disease.
    Adiga A; Goldfarb DS
    Adv Chronic Kidney Dis; 2020 Jan; 27(1):72-76. PubMed ID: 32147005
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 5-ASA therapy and renal function in inflammatory bowel disease.
    Siveke JT; Egert J; Sitter T; Schiemann U; Walcher P; Török HP; Glas J; Folwaczny C
    Am J Gastroenterol; 2005 Feb; 100(2):501. PubMed ID: 15667517
    [No Abstract]   [Full Text] [Related]  

  • 15. Estimating the prevalence of inflammatory bowel disease in Portugal using a pharmaco-epidemiological approach.
    Azevedo LF; Magro F; Portela F; Lago P; Deus J; Cotter J; Cremers I; Vieira A; Peixe P; Caldeira P; Lopes H; Gonçalves R; Reis J; Cravo M; Barros L; Ministro P; Lurdes M; Duarte A; Campos M; Carvalho L; Costa-Pereira A
    Pharmacoepidemiol Drug Saf; 2010 May; 19(5):499-510. PubMed ID: 20306455
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 5-aminosalicylic acids and the risk of renal disease: a large British epidemiologic study.
    Van Staa TP; Travis S; Leufkens HG; Logan RF
    Gastroenterology; 2004 Jun; 126(7):1733-9. PubMed ID: 15188168
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sulfasalazine, 5-ASA and acute pancreatitis in crohn's disease.
    Debongnie JC; Dekoninck X
    J Clin Gastroenterol; 1994 Dec; 19(4):348-9. PubMed ID: 7876525
    [No Abstract]   [Full Text] [Related]  

  • 18. Pancreatitis in inflammatory bowel diseases.
    Pitchumoni CS; Rubin A; Das K
    J Clin Gastroenterol; 2010 Apr; 44(4):246-53. PubMed ID: 20087199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. 5-ASA induced interstitial nephritis in patients with inflammatory bowel disease: a systematic review.
    Moss JG; Parry CM; Holt RCL; McWilliam SJ
    Eur J Med Res; 2022 Apr; 27(1):61. PubMed ID: 35488310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Late onset interstitial nephritis associated with mesalazine treatment.
    Popoola J; Muller AF; Pollock L; O'Donnell P; Carmichael P; Stevens P
    BMJ; 1998 Sep; 317(7161):795-7. PubMed ID: 9740571
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.